← 홈

폐암 (NSCLC)

365개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 365개
ADCBiologicAstraZenecaPhase 2

Cediranib (Cediranib)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 26%임상시험 54상태 RECRUITING
ADCBiologicPfizerPhase 3

Docetaxel monotherapy (Docetaxel monotherapy)

Non-small Cell Carcinoma; Non-Small Cell Lung Cancer Metastatic · Non-small Cell Carcinoma

#Non-smallCellCarcinoma#ADC#Phase3#인기#항체약물접합체+3
효능 ORR 95%임상시험 54상태 RECRUITING
ADCBiologicPfizerderuxtecan have preventive …Phase 2

lorlatinib (lorlatinib)

Non-Small Cell Lung Cancer · Cancer

#Cancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 75.8%임상시험 52상태 DISCONTINUED
AntibodyJanssenderuxtecan, datopotamab der…Phase 3

Amivantamab (Amivantamab)

Carcinoma, Non-Small-Cell Lung · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#인기#항체+5
효능 ORR 4.3%임상시험 51상태 RECRUITING
ADCBiologicAmgenbiodistributionPhase 2

Sotorasib (Sotorasib)

Colorectal Cancer; Resectable Colorectal Carcinoma · Locally Advanced Lung Non-Small Cell Car

#LocallyAdvancedLungNon-SmallCell#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 0%임상시험 51상태 RECRUITING
ADCBiologicPharmaMarderuxtecan in patients with…Phase 3

Lurbinectedin (Lurbinectedin)

Small-cell Lung Cancer; Relapsed Small Cell Lung Cancer · Small Cell Lung Cancer

#SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 40.7%임상시험 48상태 RECRUITING
CGTBiologicBiohaven Pharmaceuticals, Inc.Phase 3

Autologous cytokine-induced killer cell (Autologous cytokine-induced killer cell)

Non-small Cell Lung Cancer · Small Cell Lung Cancer

#SmallCellLungCancer#CGT#Phase3#세포유전치료#CAR-T+4
임상시험 46상태 ACTIVE
ADCBiologicPfizerderuxtecan showed encouragi…Phase 1

Dacomitinib (Dacomitinib)

Non-Small Cell Lung Cancer · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 75.3%임상시험 46상태 DISCONTINUED
ADCBiologicAstraZenecaDeruxtecan-Dlnk Quantificat…Approved

Dato-DXd (Datopotamab Deruxtecan, Datopotamab Deruxtecan (Dato-DXd))

Advanced Solid Malignancies · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Approved#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 79%임상시험 43상태 RECRUITING
ADCBiologicEMD Serono Research & Developme…Phase 3

M7824 (M7824)

Non-small Cell Lung Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 62.5%임상시험 43상태 DISCONTINUED
AntibodyRocheatApproved

bevacizumab [Avastin] (bevacizumab [Avastin])

Non-Squamous Non-Small Cell Lung Cancer · Pancreatic Cancer

#PancreaticCancer#Antibody#Approved#항체#면역항체+5
효능 ORR 83%임상시험 43상태 ACTIVE
ADCBiologicAstraZenecadeliveryPhase 3

Ceralasertib (Ceralasertib)

Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8 · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 19%임상시험 41상태 RECRUITING
ADCBiologicMerck Sharp & Dohme LLCDeruxtecan in Patients With…Phase 2

I-DXd (Ifinatamab Deruxtecan, Ifinatamab Deruxtecan (I-DXd))

Carcinoma, Non-Small-Cell Lung · Small-Cell Lung Cancer

#Small-CellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+5
임상시험 41상태 RECRUITING
ADCBiologicCanadian Cancer Trials GroupPhase 2

Savolitinib (Savolitinib)

Prostate Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 57.1%임상시험 41상태 RECRUITING
AntibodyRegeneron PharmaceuticalsPhase 2

Fianlimab (Fianlimab)

Ovarian Cancer; Fallopian Tube Cancer · NSCLC

#NSCLC#Antibody#Phase2#항체#면역항체+5
임상시험 39상태 RECRUITING
ADCBiologicFondazione per la Medicina Pers…Phase 2

Selpercatinib (Selpercatinib)

Breast Cancer; Gastrointestinal Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 100%임상시험 38상태 ACTIVE
AntibodyGlaxoSmithKlinesPhase 3

Tarlatamab (Tarlatamab)

Neoplasms · Extensive-Stage Small Cell Lung Cancer

#Extensive-StageSmallCellLungCanc#Antibody#Phase3#항체#면역항체+4
효능 ORR 57.1%임상시험 36상태 RECRUITING
ADCBiologicBeijing Biostar Pharmaceuticals…Phase 2

Utidelone (Utidelone)

Non-small Cell Lung Cancer Patients with Brain Metastases · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 36상태 RECRUITING
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Ipilimumab plus nivolumab)

Melanoma; Non Small Cell Lung Cancer · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 77.8%임상시험 32상태 RECRUITING
ADCBiologicAkesoaxisPhase 3

Platinum chemotherapy (Platinum chemotherapy)

Advanced Non Small Cell Lung Cancer (NSCLC) · Advanced Non Small Cell Lung Cancer (NSC

#AdvancedNonSmallCellLungCancerNS#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 65.1%임상시험 32상태 RECRUITING

3 / 19 페이지

← 이전다음 →